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Abstract
A 38-year-old female presented with an acute flare of ulcerative colitis. She was started on
prednisone and mesalamine. Within 24 hours of initiating mesalamine, she
developed sinus bradycardia. After holding mesalamine, the heart rate returned to normal
within five days. Our case illustrates the third described case, to our knowledge, of severe
sinus bradycardia secondary to mesalamine.
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Introduction
Since the 1960s, mesalamine was used to treat ulcerative colitis [1]. Mesalamine has shown
safety and efficacy in treating ulcerative colitis [2]. Here we describe the third known case of
mesalamine inducing bradycardia [3].
Case Presentation
A 38-year-old female presented to the hospital with complaints of lower abdominal pain and
diarrhea with rectal bleeding for two weeks. She had a history of iron deficiency anemia and
ulcerative colitis. Family history was significant for hypertension in both parents. She was
diagnosed with ulcerative colitis six years prior with colonoscopy and biopsy. She tried
numerous regimens of sulfasalazine and mesalamine with varying levels of remission, never
requiring steroids. She last took mesalamine five years prior, with full remission. She did not
report side effects to prior mesalamine regimens. At presentation, she was not on any home
medication.
A computed tomography (CT) scan showed circumferential wall thickening and mucosal
hyperenhancement of the sigmoid colon and rectum with enlarged subcentimeter pericolonic
lymph nodes consistent with proctocolitis. Blood cultures, urine cultures, and fecal cultures
were drawn and later found to have no growth. Stool for Clostridium difficile enteric toxin was
negative. Hemoglobin was 7.3g/dL. Initial management began with intravenous fluid support,
methylprednisolone, ciprofloxacin, and metronidazole. Once the abdominal pain began
subsiding, a liquid diet and oral mesalamine were started. Within 24 hours of initiating
mesalamine, she complained of dizziness and chest pain. An electrocardiogram performed
showed sinus bradycardia at 37 bpm. On presentation to the hospital, however, she had a heart
rate of 81 bpm.
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FIGURE 1: Computed Tomography of the Abdomen
Circumferential wall thickening and mucosal hyperenhancement of the sigmoid colon and the
rectum with surrounding inflammatory changes and several subcentimeter pericolonic lymph
nodes (blue arrow).
Mesalamine was held. A cardiac workup was performed consisting of telemetry monitoring,
cardiac enzymes, and echocardiogram. Cardiac workup was negative. For four days thereafter,
the heart rate was persistently bradycardic with rates between 40-50 bpm.
FIGURE 2: Electrocardiogram Showing Sinus Bradycardia
By day five, the heart rate returned to a range of 50 to 60 beats per minute. 
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To treat the ulcerative colitis flare, intravenous methylprednisolone was changed to oral
prednisone. Biologic agents were to be considered once the acute flare subsided. She was
discharged home to follow up with gastroenterology for further workup and maintenance
medication.
Discussion
Sulfasalazine was first used to treat rheumatoid arthritis in 1942. It was applied to ulcerative
colitis in the 1960s [1]. The active component is 5-aminosalicylic acid, or 5-ASA, along with
sulfapyridine [4]. Mesalamine has a half life of approximately 25 hours (Delzicol (R) oral
delayed-release capsules, mesalamine oral delayed-release capsules).
Side effects reported include intolerance, nausea, vomiting, skin eruptions, pancreatitis,
hepatotoxicity, eosinophilic pneumonitis, and arthralgia. It is reported that 45% of patients
receiving 5-ASA compounds experience an adverse reaction to some degree [5]. Its effects on
the molecular level include inhibition of the activity of the nuclear factor-kappa B (NF-κB)
pathway, inhibition of intestinal epithelial cell injury, inhibition of chemoattractant
leukotrienes, and modulation of prostaglandin metabolism [6]. Prostaglandin administration
has been shown to increase heart rate in experimental models [7-8]. Modulating the effect of
prostaglandins may be contributory to the pathomechanism of bradycardia, as reported in our
case report.
Sinus bradycardia has been reported earlier with mesalamine use [3,9]. Since the patient has
had mesalamine in the past, a predisposing factor must be present which promotes bradycardia.
The patient was not on any home medication and no new medications were started during this
hospitalization.
Conclusions
Our case is the third described case of mesalamine associated bradycardia. The patient was not
rechallenged with mesalamine, and thus cannot fully prove causality. Although literature
shows evidence that prostaglandin may play a role in altering heart rate, further research needs
to be performed in order to understand the mechanism of action on the cardiovascular system
as well as the side effects of mesalamine. Also, further research needs to clarify if there are
susceptibilities to adverse conduction related abnormalities as a result of exposure to this class
of medications.
Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study. Conflicts of interest:
In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: All authors have declared that no financial support was received from
any organization for the submitted work. Financial relationships: All authors have declared
that they have no financial relationships at present or within the previous three years with any
organizations that might have an interest in the submitted work. Other relationships: All
authors have declared that there are no other relationships or activities that could appear to
have influenced the submitted work.
References
1. Baron JH, Connell AM, Lennard-Jones JE, Jones FA: Sulphasalazine and
salicylazosulphadimidine in ulcerative colitis. Lancet. 1962, 1:1094-1096. 10.1016/S0140-
6736(62)92080-9
2018 Krzyzak et al. Cureus 10(4): e2425. DOI 10.7759/cureus.2425 3 of 4
2. Miner P Jr, Hanauer S, Robinson M, Schwartz J, Arora S: Safety and efficacy of controlled-
release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci. 1995,
40:296-304. 10.1007/BF02065413
3. Asirvatham S, Sebastian C, Thadani U: Severe symptomatic sinus bradycardia associated with
mesalamine use. Am J Gastroenterol. 1998, 93:470-471. 10.1111/j.1572-0241.1998.468_2.x
4. Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic
moiety of sulphasalazine. Lancet. 1977, 310:892-895. 10.1016/S0140-6736(77)90831-5
5. Lichtenstein GR, Blonski W, Mudireddy PRS: Atsushi: Medical Therapy of Ulcerative Colitis .
Springer, New York; 2014.
6. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid -
new evidence. Aliment Pharmacol Ther. 2006, 24:2-9. 10.1111/j.1365-2036.2006.03069.x
7. Rao TS, Seth SD, Manchanda SC, Nayar U: The involvement of the sympathetic nervous
system in the centrogenic pressor and tachycardiac effects of prostaglandins E2 and F2 alpha
in anaesthetised cats. Brain Res. 1987, 435:7-14. 10.1016/0006-8993(87)91580-0
8. Gillis RA, Quest JA, Souza JD, Kot PA, Ramwell PW: Blood pressure and heart rate effects of
prostaglandin E2 and F2 alpha produced by intracerebroventricular injections in cats.
Prostaglandins. 1981, 22:1003-1012. 10.1016/0090-6980(81)90027-7
9. Barquero-Romero J, Arrobas-Vacas J, López-Santamaría JL, López-Santamaría C: Sinus
bradycardia associated with mesalazine (article in Spanish). Med Clin (Barc). 2006, 126:639.
10.1157/13087725
2018 Krzyzak et al. Cureus 10(4): e2425. DOI 10.7759/cureus.2425 4 of 4
